Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX + fruquintinib + sintilimab perioperative phase II study in resectable locally advanced gastric/GEJ adenocarcinoma
ChiCTR2400084194Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib, sintilimab, oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Pathologic complete response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
fruquintinibsintilimaboxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400084194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084194.